ME02907B - Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kisjeline - Google Patents
Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kisjelineInfo
- Publication number
- ME02907B ME02907B MEP-2017-249A MEP2017249A ME02907B ME 02907 B ME02907 B ME 02907B ME P2017249 A MEP2017249 A ME P2017249A ME 02907 B ME02907 B ME 02907B
- Authority
- ME
- Montenegro
- Prior art keywords
- dihydro
- inden
- dioxo
- oxo
- trifluoromethyl
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- JDARDSVOVYVQST-MRXNPFEDSA-N 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluoromethyl)-2,3-dihydro-1h-inden-1-yl]pyrimidine-5-carboxylic acid Chemical compound C1CC(C(=CC=C2)C(F)(F)F)=C2[C@@H]1N(C1=O)C(=O)C(C(O)=O)=CN1C1=CC=C2N(C)C(=O)OC2=C1 JDARDSVOVYVQST-MRXNPFEDSA-N 0.000 claims 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- -1 amino acid salts Chemical class 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- SIIJHNVPJFRXHJ-QAVQXTPJSA-N (2s)-2,6-diaminohexanoic acid;1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluoromethyl)-2,3-dihydro-1h-inden-1-yl]pyrimidine-5-carboxylic acid Chemical class NCCCC[C@H](N)C(O)=O.C1CC(C(=CC=C2)C(F)(F)F)=C2[C@@H]1N(C1=O)C(=O)C(C(O)=O)=CN1C1=CC=C2N(C)C(=O)OC2=C1 SIIJHNVPJFRXHJ-QAVQXTPJSA-N 0.000 claims 1
- 235000019766 L-Lysine Nutrition 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192177 | 2013-11-08 | ||
| PCT/EP2014/073801 WO2015067652A1 (de) | 2013-11-08 | 2014-11-05 | Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure |
| EP14793565.4A EP3066097B1 (de) | 2013-11-08 | 2014-11-05 | Salze von 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02907B true ME02907B (me) | 2018-04-20 |
Family
ID=49552231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-249A ME02907B (me) | 2013-11-08 | 2014-11-05 | Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kisjeline |
Country Status (32)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3338780A1 (de) | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
| CA3061444A1 (en) * | 2017-04-27 | 2018-11-01 | Bayer Aktiengesellschaft | Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
| CN114671856B (zh) * | 2020-12-25 | 2023-10-20 | 广东东阳光药业股份有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| US20250302837A1 (en) * | 2022-04-05 | 2025-10-02 | Socpra Sciences Santé Et Humaines S.E.C. | Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001295952A1 (en) * | 2000-10-19 | 2002-04-29 | Nippon Kayaku Kabushiki Kaisha | Novel remedies or preventives for angiostenosis |
| AT511788A1 (de) | 2011-07-29 | 2013-02-15 | Georg Dr Gaul | Vorrichtung zur vorgebbaren anordnung eines stents |
| CN104168779A (zh) * | 2012-03-05 | 2014-11-26 | 格拉图克技术私人有限公司 | 膳食补充剂 |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| HK1224288A1 (zh) * | 2013-11-08 | 2017-08-18 | Bayer Pharma Aktiengesellschaft | 作为类糜蛋白酶抑制剂的取代的尿嘧啶 |
-
2014
- 2014-11-05 EA EA201600381A patent/EA033132B1/ru not_active IP Right Cessation
- 2014-11-05 CN CN201480057947.4A patent/CN105658647B/zh active Active
- 2014-11-05 HU HUE14793565A patent/HUE035021T2/en unknown
- 2014-11-05 MA MA39020A patent/MA39020A1/fr unknown
- 2014-11-05 MX MX2016005971A patent/MX366848B/es active IP Right Grant
- 2014-11-05 LT LTEP14793565.4T patent/LT3066097T/lt unknown
- 2014-11-05 EP EP14793565.4A patent/EP3066097B1/de active Active
- 2014-11-05 AU AU2014345599A patent/AU2014345599B2/en active Active
- 2014-11-05 PL PL14793565T patent/PL3066097T3/pl unknown
- 2014-11-05 US US15/035,165 patent/US9926305B2/en active Active
- 2014-11-05 HR HRP20171603TT patent/HRP20171603T1/hr unknown
- 2014-11-05 JP JP2016551038A patent/JP6446051B2/ja active Active
- 2014-11-05 PT PT147935654T patent/PT3066097T/pt unknown
- 2014-11-05 RS RS20171063A patent/RS56509B1/sr unknown
- 2014-11-05 SI SI201430450T patent/SI3066097T1/sl unknown
- 2014-11-05 NO NO14793565A patent/NO3066097T3/no unknown
- 2014-11-05 UA UAA201606202A patent/UA117686C2/uk unknown
- 2014-11-05 MY MYPI2016701615A patent/MY190108A/en unknown
- 2014-11-05 AP AP2016009181A patent/AP2016009181A0/en unknown
- 2014-11-05 KR KR1020167011771A patent/KR102351418B1/ko active Active
- 2014-11-05 CA CA2929780A patent/CA2929780C/en active Active
- 2014-11-05 ME MEP-2017-249A patent/ME02907B/me unknown
- 2014-11-05 TN TN2016000170A patent/TN2016000170A1/en unknown
- 2014-11-05 ES ES14793565.4T patent/ES2645480T3/es active Active
- 2014-11-05 BR BR112016010253A patent/BR112016010253A8/pt not_active Application Discontinuation
- 2014-11-05 DK DK14793565.4T patent/DK3066097T3/da active
- 2014-11-05 WO PCT/EP2014/073801 patent/WO2015067652A1/de not_active Ceased
-
2016
- 2016-05-01 IL IL24540716A patent/IL245407B/en active IP Right Grant
- 2016-05-06 CL CL2016001096A patent/CL2016001096A1/es unknown
- 2016-05-06 PH PH12016500853A patent/PH12016500853B1/en unknown
- 2016-05-08 SA SA516371082A patent/SA516371082B1/ar unknown
-
2017
- 2017-10-25 CY CY20171101110T patent/CY1119520T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210343T1 (hr) | Soli ili ko-kristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola | |
| ME02907B (me) | Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kisjeline | |
| MD20120050A2 (en) | New agomelatine cocrystals, process for their preparation and pharmaceutical compositions containing them | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| EA201591957A1 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| MD20140073A2 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
| EP4331667A3 (en) | Compositions comprising a delivery agent and preparation thereof | |
| HRP20210044T1 (hr) | Farmaceutski prihvatljive soli beta-gvanidinopropionske kiseline sa poboljšanim svojstvima i njihova upotreba | |
| HRP20180113T1 (hr) | Uporaba metformina u kombinaciji s aktivatorom glukokinaze i kompozicije koje sadrže metformin i aktivator glukokinaze | |
| NZ701721A (en) | Amides of 2-amino-4-arylthiazole compounds and their salts | |
| JP2016535096A5 (enExample) | ||
| UA117780C2 (uk) | Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2 | |
| WO2017094031A3 (en) | Novel process for preparation of apremilast | |
| UA112407C2 (uk) | Співкристали агомелатіну, спосіб їх виготовлення і фармацевтичні композиції, що їх містять | |
| MX358669B (es) | Croman-6-iloxi-cicloalcanos sustituidos y su uso como productos farmaceuticos. | |
| PH12014500542B1 (en) | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | |
| EP2822899A4 (en) | METHOD FOR PRODUCING BIOCIDAL AND ABSORBENT PREVALENT AQUEOUS COMPOSITIONS WITH BROMINE HYDROGEN, UREA, AND SODIUM HYPOCHLORITE | |
| MX2015006807A (es) | Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas. | |
| TH1601002185A (th) | เกลือแบบใหม่ของ 1-(3-เมธิล-2-ออกโซ-2,3-ไดไฮโดร-1,3-เบนซอกซาโซล-6-อิล)-2,4- ไดออกโซ-3-[(1r)-4-(ไตรฟลูออโรเมธิล)-2,3-ไดไฮโดร-1h-อินดิน-1-อิล]-1,2,3,4- เตตระไฮโดรไพริมิดีน-5-คาร์บอกซิลิกแอซิดและการใช้เกลือดังกล่าว | |
| MX359404B (es) | Derivados del ácido cicloalcanocraboxílico como antagonistas del receptor cxcr3. | |
| TH166328A (th) | แอลคอกซิ พิแรโซล เป็นกูแอนิเลท ไซเคลส แอคติเวเตอร์ ที่ละลายได้ | |
| TH131395A (th) | ไบโซคลิกไธอะโซลที่เป็นอัลโลสเตอริกโมดูเลเตอร์ของ mglur 5 รีเซพเตอร์ (bicyclic thiazoles as allosteric modulaters of mglur5 receptors) | |
| TH131434A (th) | สารประกอบไธโออะซิเตต องค์ประกอบ และวิธีการใช้ | |
| TH133355A (th) | อนุพันธ์ 3-(เฮทเทอโรแอริล-อะมิโน)-1,2,3,4-เตตระไฮโดร-9H-คาร์บาโซล (3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivative) และการใช้งานของพวกมันเป็นสารปรับควบคุมพรอสตาแกลนดินรีเซพเตอร์ (prostaglandin receptor modulators) | |
| TH129186A (th) | สารประกอบเฮทเทอโรไซคลิก (heterocyclic compounds) ซึ่งมีประโยชน์เป็นสารยับยั้ง pdk1 (pdk1 inhibitors) |